Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU GMP Guideline Revision To Impact Chinese Pharmaceutical Export

This article was originally published in PharmAsia News

Executive Summary

The European Union has revised its Good Manufacturing Practices guideline to include quality risk management, which will come into effect in July. Analysts note that relevant corporations in China should attach great importance to this development because quality risk management represents the domestic pharmaceutical industry's weakest link. The new demand may impact the export of pharmaceutical preparations as well as medical raw materials. An expert involved in setting China's New GMP Inspectional Guidelines says that the standards follow closely those of the U.S. FDA and EU; thus the guidelines can almost satisfy the new EU GMP requirements. (Click here for more - Chinese Language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts